Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Eur J Haematol

Retrieve available abstracts of 102 articles:
HTML format

Single Articles

    September 2022
  1. HEERING G, Sasson M, Dominissini D, Shimoni A, et al
    Contemporary evaluation of acute myeloid leukemia patients with long-term survival exceeding five years.
    Eur J Haematol. 2022 Sep 21. doi: 10.1111/ejh.13864.
    PubMed     Abstract available

  2. DIAZ-SANTA J, Rodriguez-Romanos R, Coll R, Osca G, et al
    5'-nucleotidase, cytosolic ii genotype and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
    Eur J Haematol. 2022 Sep 5. doi: 10.1111/ejh.13862.
    PubMed     Abstract available

    August 2022
  3. EGNELL C, Narhinen H, Merker A, Jonsson OG, et al
    Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol.
    Eur J Haematol. 2022 Aug 25. doi: 10.1111/ejh.13848.
    PubMed     Abstract available

    July 2022
  4. GIUDICE V, Serio B, Bertolini A, Mettivier L, et al
    Implementation of International Prognostic Index with Flow Cytometry Immunophenotyping for Better Risk Stratification of Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2022 Jul 24. doi: 10.1111/ejh.13833.
    PubMed     Abstract available

    June 2022
  5. TRACY SI, Cao Q, Bachan B, Meredith M, et al
    Ph-like gene alterations and complex chromosomal abnormalities are frequent in patients with acute lymphoblastic leukemia experiencing relapse after allogeneic hematopoietic cell transplantation.
    Eur J Haematol. 2022 Jun 14. doi: 10.1111/ejh.13814.

  6. MURPHY P, Glavey S, Quinn J
    Intracranial haemorrhage in AML patients.
    Eur J Haematol. 2022;108:536.

  7. VU M, Degeling K, Thompson ER, Blombery P, et al
    Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
    Eur J Haematol. 2022;108:469-485.
    PubMed     Abstract available

  8. KEEGAN A, Dennington PM, Dhondy N, Mulligan SP, et al
    Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection.
    Eur J Haematol. 2022;108:460-468.
    PubMed     Abstract available

    May 2022
  9. KOLONEN A, Sinisalo M, Huhtala H, Rimpilainen J, et al
    Efficacy of conventional-dose cytarabine, idarubicin and thioguanine (IAT) versus intermediate-dose cytarabine and idarubicin (IdAraC-Ida) in the induction treatment of AML: long-term results of the prospective randomized nationwide AML-2003 study by
    Eur J Haematol. 2022 May 30. doi: 10.1111/ejh.13805.
    PubMed     Abstract available

  10. ARCURI LJ, Lerner D, Tavares RCBDS
    Lower levels of cyclosporine between days 0 and +21 may reduce later relapses without increasing graft-versus-host disease in children and adolescents with acute lymphoblastic leukemia who undergo myeloablative TBI-based allogeneic hematopoietic cell
    Eur J Haematol. 2022 May 9. doi: 10.1111/ejh.13787.
    PubMed     Abstract available

  11. STUBBINS RJ, Stamenkovic M, Roy C, Rodrigo J, et al
    Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort.
    Eur J Haematol. 2022;108:437-445.
    PubMed     Abstract available

  12. VASUDEVAN NAMPOOTHIRI R, Pasic I, Law AD, Lam W, et al
    Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.
    Eur J Haematol. 2022;108:430-436.
    PubMed     Abstract available

    April 2022
  13. CLAUDIANI S, Janssen JJWM, Byrne J, Smith G, et al
    A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
    Eur J Haematol. 2022 Apr 11. doi: 10.1111/ejh.13775.
    PubMed     Abstract available

  14. CHEE L, Ritchie D, Ludford-Menting M, Ripley J, et al
    Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS).
    Eur J Haematol. 2022;108:342-353.
    PubMed     Abstract available

    March 2022
  15. GEISSLER K, Jager E, Barna A, Gurbisz M, et al
    Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
    Eur J Haematol. 2022 Mar 17. doi: 10.1111/ejh.13768.
    PubMed     Abstract available

  16. ITO T, Sanford D, Tomuleasa C, Hsiao HH, et al
    Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
    Eur J Haematol. 2022 Mar 17. doi: 10.1111/ejh.13769.
    PubMed     Abstract available

  17. MOLICA S, Giannarelli D, Montserrat E
    mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Eur J Haematol. 2022;108:264-267.

  18. WELLER JF, Mezger M, Seifert LL, Vogel W, et al
    Time-dependent analysis of adoptive immunotherapy following sequential FLAMSA-reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk myeloid neoplasia.
    Eur J Haematol. 2022;108:244-263.
    PubMed     Abstract available

    February 2022
  19. PAPAYANNIDIS C, Nanni J, Cristiano G, Marconi G, et al
    Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
    Eur J Haematol. 2022 Feb 14. doi: 10.1111/ejh.13753.
    PubMed     Abstract available

    January 2022
  20. HU R, Wei W, Mian A, Gonter-Aubin K, et al
    Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia at First Relapse.
    Eur J Haematol. 2022 Jan 18. doi: 10.1111/ejh.13744.
    PubMed     Abstract available

  21. BRIEGHEL C, Galle V, Agius R, da Cunha-Bang C, et al
    Identifying patients with chronic lymphocytic leukemia without need of treatment (CLL-WONT): end of endless watch and wait?
    Eur J Haematol. 2022 Jan 14. doi: 10.1111/ejh.13743.
    PubMed     Abstract available

  22. NOVITZKY-BASSO I, Remberger M, Chen C, Pasic I, et al
    Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts.
    Eur J Haematol. 2022;108:61-72.
    PubMed     Abstract available

    December 2021
  23. CORNELISSEN LL, Kreuger AL, Caram-Deelder C, Huisman MV, et al
    Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia.
    Eur J Haematol. 2021 Dec 19. doi: 10.1111/ejh.13737.
    PubMed     Abstract available

  24. NOSAKA K, Crawford B, Yi J, Kuan W, et al
    A Systematic Review of Survival Outcomes for Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma.
    Eur J Haematol. 2021 Dec 4. doi: 10.1111/ejh.13728.
    PubMed     Abstract available

  25. FLYGT H, Soderlund S, Stentoft J, Richter J, et al
    Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
    Eur J Haematol. 2021;107:617-623.
    PubMed     Abstract available

  26. SONG A, Altabbakh O, Sallman DA, Padron E, et al
    Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
    Eur J Haematol. 2021;107:609-616.
    PubMed     Abstract available

    November 2021
  27. CUNNINGHAM I, Sosa SS, Hamele-Bena D
    A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
    Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
    PubMed     Abstract available

  28. BUCHRITS S, Kozlovoski D, Gafter-Gvili A, Raanani P, et al
    Autoimmune and Inflammatory Manifestations Associated with Acute Myeloid Leukemia with Trisomy 8 - Case Series and Review of the Literature.
    Eur J Haematol. 2021 Nov 8. doi: 10.1111/ejh.13725.
    PubMed     Abstract available

  29. GUOLO F, Di Grazia C, Minetto P, Raiola AM, et al
    Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
    Eur J Haematol. 2021;107:573-582.
    PubMed     Abstract available

    October 2021
    Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2021 Oct 30. doi: 10.1111/ejh.13722.
    PubMed     Abstract available

  31. STEINGRIMSSON V, Lund SH, Dickman PW, Weibull CE, et al
    Survival, Causes of Death, and the Prognostic Role of Comorbidities in Chronic Lymphocytic Leukemia in the pre-ibrutinib era. A Population Based Study.
    Eur J Haematol. 2021 Oct 29. doi: 10.1111/ejh.13720.
    PubMed     Abstract available

  32. KOSCHADE SE, Stratmann JA, Miesbach W, Steffen B, et al
    Intracranial hemorrhage in newly diagnosed non-promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy.
    Eur J Haematol. 2021 Oct 29. doi: 10.1111/ejh.13718.
    PubMed     Abstract available

  33. TREMBLAY Z, Wong A, Otis AS, Pepin MA, et al
    Use of Midostaurin in Mixed Phenotype Acute Leukemia with FLT3 Mutation: A Case Series.
    Eur J Haematol. 2021 Oct 15. doi: 10.1111/ejh.13717.
    PubMed     Abstract available

  34. LACOMBE V, Nunes Gomes C, Robin JB, Thepot S, et al
    Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
    Eur J Haematol. 2021;107:489-496.
    PubMed     Abstract available

    September 2021
  35. KRISTJANSDOTTIR ER, Toksvang LN, Schmiegelow K, Rank CU, et al
    Prevalence of non-adherence and non-compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival.
    Eur J Haematol. 2021 Sep 25. doi: 10.1111/ejh.13711.
    PubMed     Abstract available

  36. KUIJVENHOVEN MA, Wilhelm AJ, Meijer E, Janssen JJWM, et al
    TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
    Eur J Haematol. 2021;107:364-369.
    PubMed     Abstract available

  37. NOVITZKY-BASSO I, Chen C, Chen S, Lipton JH, et al
    Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR.
    Eur J Haematol. 2021;107:354-363.
    PubMed     Abstract available

  38. NGAI LL, Ma CY, Maguire O, Do AD, et al
    Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
    Eur J Haematol. 2021;107:343-353.
    PubMed     Abstract available

  39. CRYSANDT M, Soysal H, Jennes E, Holtick U, et al
    Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility.
    Eur J Haematol. 2021;107:324-332.
    PubMed     Abstract available

  40. VERLINDEN A, Schroyens WA, Gadisseur AP
    Clinical and microbiological impact of long-term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia.
    Eur J Haematol. 2021;107:377-379.

  41. ATTMAN E, Syrjanen J, Lyytikainen O, Ollgren J, et al
    Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.
    Eur J Haematol. 2021;107:311-317.
    PubMed     Abstract available

    August 2021
  42. RAUTENBERG C, Lauseker M, Kaivers J, Jager P, et al
    Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
    Eur J Haematol. 2021;107:283-292.
    PubMed     Abstract available

    July 2021
  43. GRIFFIN JD, Song Y, Yang H, Freimark J, et al
    Posttransplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13692.
    PubMed     Abstract available

  44. MORTENSEN JB, Monrad I, Enemark MB, Ludvigsen M, et al
    Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Eur J Haematol. 2021;107:81-91.
    PubMed     Abstract available

  45. BRAGA LEMOS M, Rodrigues SR, Schroeder T, Kulasekararaj AG, et al
    Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.
    Eur J Haematol. 2021;107:3-23.
    PubMed     Abstract available

    June 2021
  46. PUNGOLINO E, D'adda M, De Canal G, Trojani A, et al
    Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: final report of the PhilosoPhi34 study.
    Eur J Haematol. 2021 Jun 17. doi: 10.1111/ejh.13680.
    PubMed     Abstract available

  47. MORABITO F, Tripepi G, Vigna E, Bossio S, et al
    Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
    Eur J Haematol. 2021;106:831-835.
    PubMed     Abstract available

    May 2021
  48. MACHHERNDL-SPANDL S, Jager E, Barna A, Gurbisz M, et al
    Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukemia.
    Eur J Haematol. 2021 May 16. doi: 10.1111/ejh.13647.
    PubMed     Abstract available

  49. JONSDOTTIR G, Bjorkholm M, Turesson I, Hultcrantz M, et al
    Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
    Eur J Haematol. 2021 May 9. doi: 10.1111/ejh.13650.
    PubMed     Abstract available

  50. JACOBSEN N, Frisch T, Keiding N, Heilmann C, et al
    High preharvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.
    Eur J Haematol. 2021;106:643-653.
    PubMed     Abstract available

  51. KLYUCHNIKOV E, Christopeit M, Badbaran A, Bacher U, et al
    Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML.
    Eur J Haematol. 2021;106:606-615.
    PubMed     Abstract available

    April 2021
  52. TEY A, Shaw B, Cardamone L, Shepherd S, et al
    Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
    Eur J Haematol. 2021 Apr 7. doi: 10.1111/ejh.13631.
    PubMed     Abstract available

  53. BARTELS S, Vogtmann J, Schipper E, Busche G, et al
    Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
    Eur J Haematol. 2021;106:520-528.
    PubMed     Abstract available

    March 2021
  54. BOUVIER A, Hamel JF, Delaunay J, Delabesse E, et al
    Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial.
    Eur J Haematol. 2021 Mar 25. doi: 10.1111/ejh.13626.
    PubMed     Abstract available

  55. DROZD-SOKOLOWSKA J, Karakulska-Prystupiuk E, Biecek P, Kobylinska K, et al
    Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
    Eur J Haematol. 2021 Mar 25. doi: 10.1111/ejh.13628.
    PubMed     Abstract available

  56. JOUZIER C, Hamel JF, Dumas PY, Delaunay J, et al
    Conventional chemotherapy for Acute Myeloid Leukemia in older adults: impact on nutritional, cognitive and functional status.
    Eur J Haematol. 2021 Mar 18. doi: 10.1111/ejh.13624.
    PubMed     Abstract available

  57. JEYAKUMAR N, Aldoss I, Yang D, Mokhtari S, et al
    Cytokine Gene Polymorphisms are Associated with Response to Blinatumomab in B Cell Acute Lymphoblastic Leukemia.
    Eur J Haematol. 2021 Mar 15. doi: 10.1111/ejh.13622.
    PubMed     Abstract available

  58. KATSARAKI K, Adamopoulos PG, Papageorgiou SG, Pappa V, et al
    A 3' tRNA-derived fragment produced by tRNA(LeuAAG) and tRNA(LeuTAG) is associated with poor prognosis in B-cell chronic lymphocytic leukemia, independently of classical prognostic factors.
    Eur J Haematol. 2021 Mar 4. doi: 10.1111/ejh.13613.
    PubMed     Abstract available

    February 2021
  59. CORTES JE, Kantarjian HM, Mauro MJ, An F, et al
    Long-Term Cardiac, Vascular, Hypertensive and Effusion Safety of Bosutinib in Patients With Philadelphia Chromosome-Positive Leukemia Resistant or Intolerant to Prior Therapy.
    Eur J Haematol. 2021 Feb 26. doi: 10.1111/ejh.13608.
    PubMed     Abstract available

  60. SOLANA-ALTABELLA A, Boluda B, Rodriguez-Veiga R, Cano I, et al
    Healthcare Resource Utilization in Adult Patients with Relapsed/Refractory FLT3 mutated Acute Myeloid Leukemia: A Retrospective Chart Review from Spain.
    Eur J Haematol. 2021 Feb 20. doi: 10.1111/ejh.13604.
    PubMed     Abstract available

  61. HAGGLUND H, Yavuz AS, Dreimane A, Malm C, et al
    Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.
    Eur J Haematol. 2021;106:290-293.
    PubMed     Abstract available

    January 2021
  62. GEISSLER K, Jager E, Barna A, Graf T, et al
    Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
    Eur J Haematol. 2021 Jan 12. doi: 10.1111/ejh.13577.
    PubMed     Abstract available

  63. MONTORO J, Roldan E, Pinana JL, Barba P, et al
    Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
    Eur J Haematol. 2021;106:114-125.
    PubMed     Abstract available

  64. GAMBACORTI-PASSERINI C, Chen C, Davis C, Sen GP, et al
    Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data.
    Eur J Haematol. 2021;106:82-89.
    PubMed     Abstract available

    December 2020
  65. MORABITO F, Tripepi G, Del Poeta G, Romana Mauro F, et al
    Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
    Eur J Haematol. 2020 Dec 30. doi: 10.1111/ejh.13573.
    PubMed     Abstract available

  66. QUEUDEVILLE M, Schlegel P, Heinz AT, Lenz T, et al
    Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Eur J Haematol. 2020 Dec 15. doi: 10.1111/ejh.13569.
    PubMed     Abstract available

  67. SEKINE M, Kameda T, Shide K, Maeda K, et al
    Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Dec 10. doi: 10.1111/ejh.13565.
    PubMed     Abstract available

    November 2020
  68. PICARDI M, Giordano C, Della Pepa R, Cerchione C, et al
    Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol 2020; 105: 667-671."
    Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558.
    PubMed     Abstract available

  69. STEINGRIMSSON V, Gislason GK, Thornorsteinsdottir S, Rognvaldsson S, et al
    A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
    Eur J Haematol. 2020 Nov 19. doi: 10.1111/ejh.13553.
    PubMed     Abstract available

  70. KIMURA Y, Iwanaga E, Iwanaga K, Endo S, et al
    A regulatory element in the 3'-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.
    Eur J Haematol. 2020 Nov 16. doi: 10.1111/ejh.13551.
    PubMed     Abstract available

  71. MOLICA S, Baumann T, Giannarelli D
    Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: results of a comparative performance analysis.
    Eur J Haematol. 2020 Nov 15. doi: 10.1111/ejh.13548.
    PubMed     Abstract available

  72. MACHNICKI MM, Gorniak P, Pepek M, Szymczyk A, et al
    Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Eur J Haematol. 2020 Nov 15. doi: 10.1111/ejh.13550.
    PubMed     Abstract available

  73. CANAANI J, Danylesko I, Shemtov N, Zlotnick M, et al
    A phase II study of Bisantrene in patients with relapsed/refractory acute myeloid leukemia.
    Eur J Haematol. 2020 Nov 6. doi: 10.1111/ejh.13544.
    PubMed     Abstract available

  74. SANCHEZ-PINA JM, Rodriguez Rodriguez M, Castro Quismondo N, Gil Manso R, et al
    Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
    Eur J Haematol. 2020;105:597-607.
    PubMed     Abstract available

    October 2020
  75. UCHIDA Y, Yoshimitsu M, Hachiman M, Kusano S, et al
    RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Oct 24. doi: 10.1111/ejh.13540.
    PubMed     Abstract available

  76. RAGHUNATHAN V, Fan G, Kittai AS, Okada C, et al
    A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
    Eur J Haematol. 2020 Oct 22. doi: 10.1111/ejh.13538.
    PubMed     Abstract available

  77. BELLMANN-WEILER R, Burkert F, Schwaiger T, Schmidt S, et al
    Janus-faced course of COVID-19 infection in patients with hematological malignancies.
    Eur J Haematol. 2020;105:502-504.

    September 2020
  78. ZUCENKA A, Pileckyte R, Trociukas I, Peceliunas V, et al
    Outcomes of Relapsed or Refractory Acute Myeloid Leukemia Patients Failing Venetoclax Based Salvage Therapies.
    Eur J Haematol. 2020 Sep 30. doi: 10.1111/ejh.13527.
    PubMed     Abstract available

  79. OFRAN Y, Leiba R, Frisch A, Horesh N, et al
    Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
    Eur J Haematol. 2020 Sep 18. doi: 10.1111/ejh.13518.
    PubMed     Abstract available

  80. EGNELL C, Ranta S, Banerjee J, Merker A, et al
    Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols.
    Eur J Haematol. 2020 Sep 10. doi: 10.1111/ejh.13517.
    PubMed     Abstract available

  81. JOHANSSON P, Klein-Hitpass L, Roth A, Mollmann M, et al
    Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
    Eur J Haematol. 2020 Sep 2. doi: 10.1111/ejh.13511.
    PubMed     Abstract available

  82. BAECKLUND F, Ekberg S, Rosenquist R, Askling J, et al
    Concordance in survival among first-degree relatives diagnosed with indolent lymphoid malignancies including chronic lymphocytic leukemia.
    Eur J Haematol. 2020 Sep 1. doi: 10.1111/ejh.13510.
    PubMed     Abstract available

    August 2020
  83. ISHIKAWA C, Mori N
    The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
    Eur J Haematol. 2020 Aug 11. doi: 10.1111/ejh.13508.
    PubMed     Abstract available

  84. ROBAK P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, et al
    Bone lesions in hairy cell leukemia: Diagnosis and treatment.
    Eur J Haematol. 2020 Aug 5. doi: 10.1111/ejh.13505.
    PubMed     Abstract available

  85. YOURON P, Singh C, Jindal N, Malhotra P, et al
    Quality of Life in patients of Chronic Lymphocytic Leukemia using the EORTC QLQ-C30 and QLQ-CLL17 Questionnaire.
    Eur J Haematol. 2020 Aug 3. doi: 10.1111/ejh.13503.
    PubMed     Abstract available

  86. LAPPALAINEN M, Hamalainen S, Romppanen T, Pulkki K, et al
    Febrile neutropenia in patients with acute myeloid leukemia: outcome in relation to qSOFA score, C-reactive protein and blood culture findings.
    Eur J Haematol. 2020 Aug 2. doi: 10.1111/ejh.13500.
    PubMed     Abstract available

    July 2020
  87. AARUP K, Rotbain EC, Enggaard L, Pedersen RS, et al
    Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
    Eur J Haematol. 2020 Jul 31. doi: 10.1111/ejh.13499.
    PubMed     Abstract available

  88. KUZELOVA K, Obr A, Markova J, Gasova Z, et al
    Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: impact of NPM1 and FLT3 mutations.
    Eur J Haematol. 2020 Jul 15. doi: 10.1111/ejh.13488.
    PubMed     Abstract available

    June 2020
  89. LANGERBEINS P, Furstenau M, Gruell H, Klein F, et al
    COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.
    Eur J Haematol. 2020 Jun 23. doi: 10.1111/ejh.13475.
    PubMed     Abstract available

  90. STEINGRIMSSON V, Gislason GK, Aspelund T, Turesson I, et al
    A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival.
    Eur J Haematol. 2020 Jun 23. doi: 10.1111/ejh.13477.
    PubMed     Abstract available

  91. ISHIKAWA C, Mori N
    MALT-1 as a novel therapeutic target for adult T-cell leukemia.
    Eur J Haematol. 2020 Jun 23. doi: 10.1111/ejh.13467.
    PubMed     Abstract available

  92. SATAKE A, Konishi A, Azuma Y, Tsubokura Y, et al
    Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13474.
    PubMed     Abstract available

  93. WU L, Xia M, Sun X, Han X, et al
    High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia.
    Eur J Haematol. 2020 Jun 14. doi: 10.1111/ejh.13466.
    PubMed     Abstract available

    May 2020
  94. BEZIAT G, Tavitian S, Bertoli S, Huguet F, et al
    Dactinomycin in acute myeloid leukemia with NPM1 mutations.
    Eur J Haematol. 2020 May 25. doi: 10.1111/ejh.13438.
    PubMed     Abstract available

  95. CESINI L, Frieri C, Barate C, Sora F, et al
    Erythropoietin Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib who Developed Late Anemia.
    Eur J Haematol. 2020 May 4. doi: 10.1111/ejh.13436.
    PubMed     Abstract available

    April 2020
  96. CHOI Y, Lee JH, Lee JH, Park HS, et al
    Title: Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.
    Eur J Haematol. 2020 Apr 30. doi: 10.1111/ejh.13434.
    PubMed     Abstract available

  97. THIELEN FW, van Dongen-Leunis A, Arons A, Ladestein JR, et al
    Cost-Effectiveness of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-cell acute Lymphoblastic Leukemia.
    Eur J Haematol. 2020 Apr 14. doi: 10.1111/ejh.13427.
    PubMed     Abstract available

  98. SITGES M, Boluda B, Garrido A, Morgades M, et al
    Scute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). study of 61 patients treated with intensive protocols.
    Eur J Haematol. 2020 Apr 3. doi: 10.1111/ejh.13417.
    PubMed     Abstract available

  99. GOKBUGET N, Dombret H, Giebel S, Bruggemann M, et al
    Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
    Eur J Haematol. 2020;104:299-309.
    PubMed     Abstract available

    March 2020
  100. ZAJAC-SPYCHALA O, Irga-Jaworska N, Drozynska E, Muszynska-Roslan K, et al
    Mixed phenotype acute leukemia (MPAL): biological profile, clinical characteristic and treatment outcomes: report of the population-based study.
    Eur J Haematol. 2020 Mar 28. doi: 10.1111/ejh.13413.
    PubMed     Abstract available

    February 2020
  101. DILL V, Kauschinger J, Hauch RT, Buschhorn L, et al
    Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Eur J Haematol. 2020;104:125-137.
    PubMed     Abstract available

  102. CHOI JS, Berdis A
    An artificial nucleoside that simultaneously detects and combats drug resistance to doxorubicin.
    Eur J Haematol. 2020;104:97-109.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.